Get the Daily Brief
Latest Biotech News
Boehringer reveals cGAS inhibitors; Kymera patents STAT6 tools
Two discovery disclosures landed this week: Boehringer Ingelheim reported novel cyclic GMP‑AMP synthase (cGAS) inhibitors aimed at autoinflammatory interferonopathies and fibrotic/metabolic lung...
FDA’s plausible mechanism pathway: Streamlined route for bespoke rare-disease treatments
US regulatory officials published a 'plausible mechanism pathway' in The New England Journal of Medicine proposing an expedited approval route for bespoke therapies for ultra-rare diseases. The...
NMPA clears JMT-206: CSPC moves obesity candidate to clinic
China’s National Medical Products Administration granted clinical trial clearance to CSPC Pharmaceutical Group for JMT-206, an investigational agent for weight management in people with obesity or...
SK Biopharma licenses WT‑7695: Acquires global rights to preclinical radiopharmaceutical
SK Biopharmaceuticals struck an exclusive worldwide license with the Wisconsin Alumni Research Foundation for WT‑7695, a preclinical-stage radiopharmaceutical developed with the University of...
CrisprBits nets $3M... to scale CRISPR diagnostics and R&D
Indian CRISPR diagnostics startup CrisprBits closed a US$3 million Pre‑Series A round led by Spectrum Impact, the family office of Rajendra Gogri, to expand diagnostics, gene‑editing tools and...
WGS from FFPE—New method unlocks tumor genomes for precision oncology
Researchers published a methodology enabling robust whole‑genome sequencing (WGS) from formalin‑fixed, paraffin‑embedded (FFPE) tissue, overcoming long-standing technical challenges in archival...
mRNA‑engineered MSCs: DC‑25 advances allogeneic cell immunotherapy
A team reported an mRNA engineering approach that enhances mesenchymal stem cells (MSCs) to create DC‑25, an allogeneic cell therapy candidate designed to improve immunotherapeutic potency. The...
CAR‑macrophages reverse liver fibrosis in mice—Preclinical proof
Researchers reported that CAR‑macrophage therapy reduced liver fibrosis in mouse models, providing a proof‑of‑concept for engineered innate immune cells as anti‑fibrotic agents. The study showed...
Microbial β‑glucuronidases drive colorectal cancer... New Nature Communications study
A Nature Communications paper identified gut microbial β‑glucuronidases as active drivers of metabolic changes linked to colorectal cancer, mapping how microbial enzymes reshape carcinogenic...
Off‑the‑shelf mRNA vaccines target liver cancer: Preclinical immunotherapy advance
Researchers described an off‑the‑shelf mRNA vaccine platform targeting hepatocellular carcinoma that elicits tumor‑directed immune responses in preclinical models. The study reports antigen...
Target NSD2—Reverses drug resistance in neuroendocrine prostate cancer
A Nature report showed that inhibiting the epigenetic regulator NSD2 can reverse resistance in neuroendocrine prostate cancer (a treatment‑resistant CRPC subtype), restoring sensitivity to...
Aspen raises $115m – scales autologous iPSC Parkinson’s program
Aspen Neuroscience closed a $115 million Series C to accelerate clinical development and manufacturing scale-up for ANPD001, its autologous iPSC-derived cell therapy for Parkinson’s disease. The...
mRNA engineering transforms off‑the‑shelf MSCs... DC‑25 emerges
Researchers reported an mRNA-based platform that programs mesenchymal stem cells (MSCs) to create an allogeneic cell therapy product dubbed DC-25 with enhanced immunotherapeutic properties. The...
CAR‑macrophage therapy reverses liver fibrosis in mice
A preclinical study showed CAR‑macrophage therapy significantly reduced liver fibrosis in mouse models, demonstrating improved histology and reduced fibrotic markers after treatment. The authors...
Next‑gen PRMT5 inhibitor drives antitumor activity – TNG‑456
Tango Therapeutics presented preclinical data for TNG‑456, a next‑generation PRMT5 inhibitor engineered to cooperate with MTAP-deleted tumors and showing strong antitumor activity in glioma and...
TEAD inhibitor VT‑3989 curbs NF2‑deficient tumor growth
Vivace Therapeutics disclosed preclinical efficacy for VT‑3989, a TEAD inhibitor that suppressed growth of aggressive NF2‑deficient meningioma models and other TEAD‑driven tumors. Data included...
Boehringer finds cGAS inhibitors – new tools against interferonopathies
Boehringer Ingelheim disclosed discovery of novel cGAS inhibitors aimed at treating autoinflammatory interferonopathies, idiopathic pulmonary fibrosis, NASH/MASH and related immune-driven...
Kymera patents STAT6 inhibitors – expanding inflammation and oncology reach
Kymera Therapeutics filed patents describing STAT6 inhibitors intended for a broad range of indications including cancer, inflammatory disorders and neurodegeneration. The patent disclosures...
Protein‑degradation race: Blueprint’s CDK4 PROTAC and Gluetacs’ molecular glues
Two filings underscore momentum in targeted protein degradation: Blueprint Medicines disclosed PROTAC degraders directed at CDK4, while Gluetacs Therapeutics reported novel cereblon‑based...
Eli Lilly discloses RXFP1 agonists – cardio‑renal pipeline expansion
Eli Lilly disclosed a new series of RXFP1 (relaxin receptor 1) agonists with potential utility across pulmonary hypertension, acute and chronic kidney disease, diabetic nephropathy and COPD. The...